MicroRNAs como biomarcadores de diagnóstico, pronóstico y predicción en cáncer de mama
DOI:
https://doi.org/10.29105/bys8.15-164Keywords:
Breast cancer, biomarkers, miRNAsAbstract
Breast cancer is the most prevalent type of cancer in women, exerting a significant impact on global public health. Given its complexity and high heterogeneity, it is essential to conduct a prompt and effective diagnosis to determine the disease's prognosis and administer appropriate treatment to affected patients. Therefore, the utilization of microRNAs as biomarkers would greatly facilitate the diagnosis and prognosis of this disease. With their multiple characteristics, microRNAs emerge as ideal candidates for implementation as biomarkers in cancer. This article delves into the significance of microRNAs as diagnostic, prognostic, and predictive biomarkers in breast cancer.
Downloads
References
Ahmad, A. (Ed.). (2019). Breast Cancer Metastasis and Drug Resistance: Challenges and Progress (Vol. 1152). Springer International Publishing. https://doi.org/10.1007/978-3-030-20301-6 DOI: https://doi.org/10.1007/978-3-030-20301-6
American Cancer Society. (s. f.). Breast Cancer Facts & Figures 2019-2020.
Andorfer, C. A., Necela, B. M., Thompson, E. A., & Perez, E. A. (2011). MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer. Trends in Molecular Medicine, 17(6), 313-319. https://doi.org/10.1016/j.molmed.2011.01.006 DOI: https://doi.org/10.1016/j.molmed.2011.01.006
Bartel, D. P. (2004). MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell, 116(2), 281-297. https://doi.org/10.1016/S0092-8674(04)00045-5 DOI: https://doi.org/10.1016/S0092-8674(04)00045-5
Bertoli, G., Cava, C., & Castiglioni, I. (2015). MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics, 5(10), 1122-1143. https://doi.org/10.7150/thno.11543 DOI: https://doi.org/10.7150/thno.11543
Chakrabortty, A., Patton, D. J., Smith, B. F., & Agarwal, P. (2023). miRNAs: Potential as Biomarkers and Therapeutic Targets for Cancer. Genes, 14(7), Article 7. https://doi.org/10.3390/genes14071375 DOI: https://doi.org/10.3390/genes14071375
Christodoulatos, G. S., & Dalamaga, M. (2014). Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? World Journal of Clinical Oncology, 5(2), 71-81. https://doi.org/10.5306/wjco.v5.i2.71 DOI: https://doi.org/10.5306/wjco.v5.i2.71
Dong, G., Liang, X., Wang, D., Gao, H., Wang, L., Wang, L., Liu, J., & Du, Z. (2014). High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Medical Oncology (Northwood, London, England), 31(7), 57. https://doi.org/10.1007/s12032-014-0057-x DOI: https://doi.org/10.1007/s12032-014-0057-x
Finnegan, E. F., & Pasquinelli, A. E. (2013). MicroRNA biogenesis: Regulating the regulators. Critical Reviews in Biochemistry and Molecular Biology, 48(1), 51-68. https://doi.org/10.3109/10409238.2012.738643 DOI: https://doi.org/10.3109/10409238.2012.738643
Gasparini, P., Cascione, L., Fassan, M., Lovat, F., Guler, G., Balci, S., Irkkan, C., Morrison, C., Croce, C. M., Shapiro, C. L., & Huebner, K. (2014). microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget, 5(5), 1174-1184. https://doi.org/10.18632/oncotarget.1682 DOI: https://doi.org/10.18632/oncotarget.1682
Ho, P. T. B., Clark, I. M., & Le, L. T. T. (2022). MicroRNA-Based Diagnosis and Therapy. International Journal of Molecular Sciences, 23(13), Article 13. https://doi.org/10.3390/ijms23137167 DOI: https://doi.org/10.3390/ijms23137167
Hu, J., Xu, J., Wu, Y., Chen, Q., Zheng, W., Lu, X., Zhou, C., & Jiao, D. (2015). Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 36(1), 251-258. https://doi.org/10.1007/s13277-014-2611-8 DOI: https://doi.org/10.1007/s13277-014-2611-8
Hu, Z., Dong, J., Wang, L.-E., Ma, H., Liu, J., Zhao, Y., Tang, J., Chen, X., Dai, J., Wei, Q., Zhang, C., & Shen, H. (2012). Serum microRNA profiling and breast cancer risk: The use of miR-484/191 as endogenous controls. Carcinogenesis, 33(4), 828-834. https://doi.org/10.1093/carcin/bgs030 DOI: https://doi.org/10.1093/carcin/bgs030
INEGI. (s. f.). Instituto Nacional de Estadística y Geografía. INEGI. Recuperado 29 de noviembre de 2023, de https://www.inegi.org.mx/app/saladeprensa/noticia.html?id=8498
Institut Claudius Regaud. (2018). Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer? Pilot Study. (Clinical trial registration NCT01612871). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT01612871
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., Ménard, S., Palazzo, J. P., Rosenberg, A., Musiani, P., Volinia, S., Nenci, I., Calin, G. A., Querzoli, P., Negrini, M., & Croce, C. M. (2005). MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 65(16), 7065-7070. https://doi.org/10.1158/0008-5472.CAN-05-1783 DOI: https://doi.org/10.1158/0008-5472.CAN-05-1783
Jung, E.-J., Santarpia, L., Kim, J., Esteva, F. J., Moretti, E., Buzdar, A. U., Di Leo, A., Le, X.-F., Bast, R. C., Park, S.-T., Pusztai, L., & Calin, G. A. (2012). Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 118(10), 2603-2614. https://doi.org/10.1002/cncr.26565 DOI: https://doi.org/10.1002/cncr.26565
Krishnan, P., Ghosh, S., Wang, B., Li, D., Narasimhan, A., Berendt, R., Graham, K., Mackey, J. R., Kovalchuk, O., & Damaraju, S. (2015). Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics, 16(1), 735. https://doi.org/10.1186/s12864-015-1899-0 DOI: https://doi.org/10.1186/s12864-015-1899-0
Kulasingam, V., & Diamandis, E. P. (2008). Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nature Clinical Practice. Oncology, 5(10), 588-599. https://doi.org/10.1038/ncponc1187 DOI: https://doi.org/10.1038/ncponc1187
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), Article 5. https://doi.org/10.1016/0092-8674(93)90529-Y DOI: https://doi.org/10.1016/0092-8674(93)90529-Y
Lujambio, A., & Lowe, S. W. (2012). The microcosmos of cancer. Nature, 482(7385), Article 7385. https://doi.org/10.1038/nature10888 DOI: https://doi.org/10.1038/nature10888
Lyng, M. B., Lænkholm, A.-V., Søkilde, R., Gravgaard, K. H., Litman, T., & Ditzel, H. J. (2012). Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: A DBCG study. PloS One, 7(5), e36170. https://doi.org/10.1371/journal.pone.0036170 DOI: https://doi.org/10.1371/journal.pone.0036170
Moazed, D. (2009, enero 21). Small RNAs in transcriptional gene silencing and genome defence [Special Features]. Nature. https://doi.org/10.1038/nature07756 DOI: https://doi.org/10.1038/nature07756
NCI (nciglobal,ncienterprise). (2011, febrero 2). [nciAppModulePage]. https://www.cancer.gov/espanol/publicaciones/diccionarios/diccionario-cancer/def/biomarcador
Peng, S., Wang, J., Wei, S., Li, C., Zhou, K., Hu, J., Ye, X., Yan, J., Liu, W., Gao, G. F., Fang, M., & Meng, S. (2018). Endogenous Cellular MicroRNAs Mediate Antiviral Defense against Influenza A Virus. Molecular Therapy - Nucleic Acids, 10, 361-375. https://doi.org/10.1016/j.omtn.2017.12.016 DOI: https://doi.org/10.1016/j.omtn.2017.12.016
Provenzano, E., Ulaner, G. A., & Chin, S.-F. (2018). Molecular Classification of Breast Cancer. PET Clinics, 13(3), Article 3. https://doi.org/10.1016/j.cpet.2018.02.004 DOI: https://doi.org/10.1016/j.cpet.2018.02.004
Purkayastha, K., Dhar, R., Pethusamy, K., Srivastava, T., Shankar, A., Rath, G. K., & Karmakar, S. (2023). The issues and challenges with cancer biomarkers. Journal of Cancer Research and Therapeutics, 19(Suppl 1), S20. https://doi.org/10.4103/jcrt.jcrt_384_22 DOI: https://doi.org/10.4103/jcrt.jcrt_384_22
Roth, C., Rack, B., Müller, V., Janni, W., Pantel, K., & Schwarzenbach, H. (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research: BCR, 12(6), R90. https://doi.org/10.1186/bcr2766 DOI: https://doi.org/10.1186/bcr2766
Rothé, F., Ignatiadis, M., Chaboteaux, C., Haibe-Kains, B., Kheddoumi, N., Majjaj, S., Badran, B., Fayyad-Kazan, H., Desmedt, C., Harris, A. L., Piccart, M., & Sotiriou, C. (2011). Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PloS One, 6(6), e20980. https://doi.org/10.1371/journal.pone.0020980 DOI: https://doi.org/10.1371/journal.pone.0020980
Sarhadi, V. K., & Armengol, G. (2022). Molecular Biomarkers in Cancer. Biomolecules, 12(8), Article 8. https://doi.org/10.3390/biom12081021 DOI: https://doi.org/10.3390/biom12081021
Sell, S. (2003). Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Eleftherios P. Diamandis, Hervert A. Fritche, Hans Lilja, Daniel W. Chan, and Morton K. Schwartz, eds. Washington, DC: AACC Press, 2002, 513 pp., $99.00 ($79.00 AACC members), softcover. ISBN 1-890883-71-9. Clinical Chemistry, 49(2), 342. https://doi.org/10.1373/49.2.342 DOI: https://doi.org/10.1373/49.2.342
Siervi, A. D. (2022). Onco-liq: Kit for Breast Cancer Diagnosis. (Clinical trial registration NCT04906330). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT04906330
Strimbu, K., & Tavel, J. A. (2010). What are Biomarkers? Current opinion in HIV and AIDS, 5(6), 463-466. https://doi.org/10.1097/COH.0b013e32833ed177 DOI: https://doi.org/10.1097/COH.0b013e32833ed177
Sun, Y., Wang, M., Lin, G., Sun, S., Li, X., Qi, J., & Li, J. (2012). Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PloS One, 7(10), e47003. https://doi.org/10.1371/journal.pone.0047003 DOI: https://doi.org/10.1371/journal.pone.0047003
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, n/a(n/a), Article n/a. https://doi.org/10.3322/caac.21660 DOI: https://doi.org/10.3322/caac.21660
Tang, J., Ahmad, A., & Sarkar, F. H. (2012). The role of microRNAs in breast cancer migration, invasion and metastasis. International Journal of Molecular Sciences, 13(10), 13414-13437. https://doi.org/10.3390/ijms131013414 DOI: https://doi.org/10.3390/ijms131013414
Tsang, J. Y. S., & Tse, G. M. (2020). Molecular Classification of Breast Cancer. Advances in Anatomic Pathology, 27(1), Article 1. https://doi.org/10.1097/PAP.0000000000000232 DOI: https://doi.org/10.1097/PAP.0000000000000232
Valabrega, G., Montemurro, F., & Aglietta, M. (2007). Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 18(6), 977-984. https://doi.org/10.1093/annonc/mdl475 DOI: https://doi.org/10.1093/annonc/mdl475
Wu, Q., Lu, Z., Li, H., Lu, J., Guo, L., & Ge, Q. (2011). Next-generation sequencing of microRNAs for breast cancer detection. Journal of Biomedicine & Biotechnology, 2011, 597145. https://doi.org/10.1155/2011/597145 DOI: https://doi.org/10.1155/2011/597145
Zhao, F., Dou, Y., Wang, X., Han, D., Lv, Z., Ge, S., & Zhang, Y. (2014). Serum microRNA-195 is down-regulated in breast cancer: A potential marker for the diagnosis of breast cancer. Molecular Biology Reports, 41(9), 5913-5922. https://doi.org/10.1007/s11033-014-3466-1 DOI: https://doi.org/10.1007/s11033-014-3466-1
